Effectiveness of romosozumab following prior raloxifene treatment in primary osteoporosis: An observational study
Romosozumab is an anti-sclerostin antibody that increases bone formation and decreases bone resorption. It has been available for patients at high risk of osteoporotic fractures in Japan since 2019. The aim of this study was to clarify the clinical effectiveness and safety of romosozumab following p...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Elsevier
2026-03-01
|
| Цуврал: | Bone Reports |
| Нөхцлүүд: | |
| Онлайн хандалт: | http://www.sciencedirect.com/science/article/pii/S2352187226000045 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|